中国武汉老年COVID-19幸存者认知变化的一年轨迹:一项纵向队列研究
这项队列研究纳入2020年2月10日至4月10日武汉3家COVID-19定点医院出院的3233名60岁及以上COVID-19幸存者,以466名未感染配偶为对照,最终1438名幸存者和438名对照完成12个月随访。幸存者出院12个月认知障碍发生率为12.45%;重症COVID-19与早发性、晚发性和进行性认知下降风险升高相关。
要点
- 幸存者出院12个月认知障碍发生率为12.45%。
- 12个月时重症组TICS-40评分低于非重症组和对照组。
- 重症COVID-19与早发性、晚发性和进行性认知下降风险升高相关。
核心结论
- 在这项队列研究中,COVID-19存活与纵向认知下降风险增加相关,突出表明立即采取措施应对这一挑战的重要性。
研究设计与样本
- 这项队列研究招募2020年2月10日至4月10日武汉3家COVID-19定点医院出院的3233名60岁及以上COVID-19幸存者,并以466名未感染配偶为对照人群。
- 排除感染前认知障碍、合并神经系统疾病、痴呆家族史以及严重心、肝、肾疾病或任何种类肿瘤者。
- 在6个月和12个月随访时监测认知功能和认知下降;最终随访纳入1438名COVID-19幸存者和438名对照个体。
- COVID-19按美国胸科学会指南分为重症或非重症。
- 认知变化分别用老年认知下降知情者问卷和认知状态电话访谈-40评估;根据两个随访期的认知变化将认知轨迹分为稳定认知、早发性认知下降、晚发性认知下降和进行性认知下降4类。
主要发现
- 在筛查的3233名COVID-19幸存者和1317名未感染配偶中,1438名接受COVID-19治疗的参与者(691名男性[48.05%]和747名女性[51.95%];中位[IQR]年龄,69[66-74]岁)和438名未感染对照个体(222名男性[50.68%]和216名女性[49.32%];中位[IQR]年龄,67[66-74]岁)完成了12个月随访。
- 幸存者出院12个月认知障碍发生率为12.45%。
- 12个月时重症组认知状态电话访谈-40评分低于非重症组和对照组(中位[IQR]:重症组22.50[16.00-28.00];非重症组30.00[26.00-33.00];对照组31.00[26.00-33.00])。
- 调整年龄、性别、教育水平、体重指数和合并症后,重症COVID-19与早发性认知下降风险升高相关(OR 4.87;95%CI 3.30-7.20)、与晚发性认知下降风险升高相关(OR 7.58;95%CI 3.58-16.03)、与进行性认知下降风险升高相关(OR 19.00;95%CI 9.14-39.51)。
- 调整年龄、性别、教育水平、体重指数和合并症后,非重症COVID-19与早发性认知下降风险升高相关(OR 1.71;95%CI 1.30-2.27)。
关键数值与推荐
- 幸存者出院12个月认知障碍发生率为12.45%。
- 12个月时认知状态电话访谈-40评分中位[IQR]:重症组22.50[16.00-28.00],非重症组30.00[26.00-33.00],对照组31.00[26.00-33.00]。
- 重症COVID-19与早发性认知下降相关(OR 4.87;95%CI 3.30-7.20)。
- 重症COVID-19与晚发性认知下降相关(OR 7.58;95%CI 3.58-16.03)。
- 重症COVID-19与进行性认知下降相关(OR 19.00;95%CI 9.14-39.51);非重症COVID-19与早发性认知下降相关(OR 1.71;95%CI 1.30-2.27)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Determining the long-term impact of COVID-19 on cognition is important to inform immediate steps in COVID-19 research and health policy. OBJECTIVE: To investigate the 1-year trajectory of cognitive changes in older COVID-19 survivors. DESIGN, SETTING, AND PARTICIPANTS: This cohort study recruited 3233 COVID-19 survivors 60 years and older who were discharged from 3 COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. Their uninfected spouses (N = 466) were recruited as a control population. Participants with preinfection cognitive impairment, a concomitant neurological disorder, or a family history of dementia were excluded, as well as those with severe cardiac, hepatic, or kidney disease or any kind of tumor. Follow-up monitoring cognitive functioning and decline took place at 6 and 12 months. A total of 1438 COVID-19 survivors and 438 control individuals were included in the final follow-up. COVID-19 was categorized as severe or nonsevere following the American Thoracic Society guidelines. MAIN OUTCOMES AND MEASURES: The main outcome was change in cognition 1 year after patient discharge. Cognitive changes during the first and second 6-month follow-up periods were assessed using the Informant Questionnaire on Cognitive Decline in the Elderly and the Telephone Interview of Cognitive Status-40, respectively. Based on the cognitive changes observed during the 2 periods, cognitive trajectories were classified into 4 categories: stable cognition, early-onset cognitive decline, late-onset cognitive decline, and progressive cognitive decline. Multinomial and conditional logistical regression models were used to identify factors associated with risk of cognitive decline. RESULTS: Among the 3233 COVID-19 survivors and 1317 uninfected spouses screened, 1438 participants who were treated for COVID-19 (691 male [48.05%] and 747 female [51.95%]; median [IQR] age, 69 [66-74] years) and 438 uninfected control individuals (222 male [50.68%] and 216 female [49.32%]; median [IQR] age, 67 [66-74] years) completed the 12-month follow-up. The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%. Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00]; nonsevere, 30.00 [26.00-33.00]; control, 31.00 [26.00-33.00]). Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20), late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03), and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51), while nonsevere COVID-19 was associated with a higher risk of early-onset cognitive decline (OR, 1.71; 95% CI, 1.30-2.27) when adjusting for age, sex, education level, body mass index, and comorbidities. CONCLUSIONS AND RELEVANCE: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
引用
- Liu YH, Chen Y, Wang QH, et al. One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study. JAMA Neurol. 2022. PMID: 35258587. doi:10.1001/jamaneurol.2022.0461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。